Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer
Background Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete respo...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Shien, Tadahiko [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2008 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Société Internationale de Chirurgie 2008 |
|---|
| Übergeordnetes Werk: |
Enthalten in: World Journal of Surgery - Springer-Verlag, 1996, 33(2008), 1 vom: 25. Okt., Seite 44-51 |
|---|---|
| Übergeordnetes Werk: |
volume:33 ; year:2008 ; number:1 ; day:25 ; month:10 ; pages:44-51 |
| Links: |
|---|
| DOI / URN: |
10.1007/s00268-008-9800-9 |
|---|
| Katalog-ID: |
SPR003420027 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR003420027 | ||
| 003 | DE-627 | ||
| 005 | 20230519101528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201001s2008 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00268-008-9800-9 |2 doi | |
| 035 | |a (DE-627)SPR003420027 | ||
| 035 | |a (SPR)s00268-008-9800-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shien, Tadahiko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer |
| 264 | 1 | |c 2008 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Société Internationale de Chirurgie 2008 | ||
| 520 | |a Background Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. Methods From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. Results The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. Conclusions In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane. | ||
| 650 | 4 | |a Trastuzumab |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Compute Tomography Imaging |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Invasive Lobular Carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tumor Shape |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Maximum Tumor Size |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Akashi-Tanaka, Sadako |4 aut | |
| 700 | 1 | |a Miyakawa, Kunihisa |4 aut | |
| 700 | 1 | |a Hojo, Takashi |4 aut | |
| 700 | 1 | |a Shimizu, Chikako |4 aut | |
| 700 | 1 | |a Seki, Kunihiko |4 aut | |
| 700 | 1 | |a Ando, Masashi |4 aut | |
| 700 | 1 | |a Kohno, Tsutomu |4 aut | |
| 700 | 1 | |a Taira, Naruto |4 aut | |
| 700 | 1 | |a Doihara, Hiroyoshi |4 aut | |
| 700 | 1 | |a Katsumata, Noriyuki |4 aut | |
| 700 | 1 | |a Fujiwara, Yasuhiro |4 aut | |
| 700 | 1 | |a Kinoshita, Takayuki |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World Journal of Surgery |d Springer-Verlag, 1996 |g 33(2008), 1 vom: 25. Okt., Seite 44-51 |w (DE-627)SPR003391159 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2008 |g number:1 |g day:25 |g month:10 |g pages:44-51 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00268-008-9800-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2008 |e 1 |b 25 |c 10 |h 44-51 | ||
| author_variant |
t s ts s a t sat k m km t h th c s cs k s ks m a ma t k tk n t nt h d hd n k nk y f yf t k tk |
|---|---|
| matchkey_str |
shientadahikoakashitanakasadakomiyakawak:2008----:lncptooiafaueotmrapeitrotefiayfrmrnoduathm |
| hierarchy_sort_str |
2008 |
| publishDate |
2008 |
| allfields |
10.1007/s00268-008-9800-9 doi (DE-627)SPR003420027 (SPR)s00268-008-9800-9-e DE-627 ger DE-627 rakwb eng Shien, Tadahiko verfasserin aut Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2008 Background Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. Methods From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. Results The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. Conclusions In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane. Trastuzumab (dpeaa)DE-He213 Compute Tomography Imaging (dpeaa)DE-He213 Invasive Lobular Carcinoma (dpeaa)DE-He213 Tumor Shape (dpeaa)DE-He213 Maximum Tumor Size (dpeaa)DE-He213 Akashi-Tanaka, Sadako aut Miyakawa, Kunihisa aut Hojo, Takashi aut Shimizu, Chikako aut Seki, Kunihiko aut Ando, Masashi aut Kohno, Tsutomu aut Taira, Naruto aut Doihara, Hiroyoshi aut Katsumata, Noriyuki aut Fujiwara, Yasuhiro aut Kinoshita, Takayuki aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 33(2008), 1 vom: 25. Okt., Seite 44-51 (DE-627)SPR003391159 nnns volume:33 year:2008 number:1 day:25 month:10 pages:44-51 https://dx.doi.org/10.1007/s00268-008-9800-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 33 2008 1 25 10 44-51 |
| spelling |
10.1007/s00268-008-9800-9 doi (DE-627)SPR003420027 (SPR)s00268-008-9800-9-e DE-627 ger DE-627 rakwb eng Shien, Tadahiko verfasserin aut Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2008 Background Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. Methods From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. Results The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. Conclusions In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane. Trastuzumab (dpeaa)DE-He213 Compute Tomography Imaging (dpeaa)DE-He213 Invasive Lobular Carcinoma (dpeaa)DE-He213 Tumor Shape (dpeaa)DE-He213 Maximum Tumor Size (dpeaa)DE-He213 Akashi-Tanaka, Sadako aut Miyakawa, Kunihisa aut Hojo, Takashi aut Shimizu, Chikako aut Seki, Kunihiko aut Ando, Masashi aut Kohno, Tsutomu aut Taira, Naruto aut Doihara, Hiroyoshi aut Katsumata, Noriyuki aut Fujiwara, Yasuhiro aut Kinoshita, Takayuki aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 33(2008), 1 vom: 25. Okt., Seite 44-51 (DE-627)SPR003391159 nnns volume:33 year:2008 number:1 day:25 month:10 pages:44-51 https://dx.doi.org/10.1007/s00268-008-9800-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 33 2008 1 25 10 44-51 |
| allfields_unstemmed |
10.1007/s00268-008-9800-9 doi (DE-627)SPR003420027 (SPR)s00268-008-9800-9-e DE-627 ger DE-627 rakwb eng Shien, Tadahiko verfasserin aut Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2008 Background Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. Methods From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. Results The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. Conclusions In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane. Trastuzumab (dpeaa)DE-He213 Compute Tomography Imaging (dpeaa)DE-He213 Invasive Lobular Carcinoma (dpeaa)DE-He213 Tumor Shape (dpeaa)DE-He213 Maximum Tumor Size (dpeaa)DE-He213 Akashi-Tanaka, Sadako aut Miyakawa, Kunihisa aut Hojo, Takashi aut Shimizu, Chikako aut Seki, Kunihiko aut Ando, Masashi aut Kohno, Tsutomu aut Taira, Naruto aut Doihara, Hiroyoshi aut Katsumata, Noriyuki aut Fujiwara, Yasuhiro aut Kinoshita, Takayuki aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 33(2008), 1 vom: 25. Okt., Seite 44-51 (DE-627)SPR003391159 nnns volume:33 year:2008 number:1 day:25 month:10 pages:44-51 https://dx.doi.org/10.1007/s00268-008-9800-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 33 2008 1 25 10 44-51 |
| allfieldsGer |
10.1007/s00268-008-9800-9 doi (DE-627)SPR003420027 (SPR)s00268-008-9800-9-e DE-627 ger DE-627 rakwb eng Shien, Tadahiko verfasserin aut Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2008 Background Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. Methods From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. Results The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. Conclusions In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane. Trastuzumab (dpeaa)DE-He213 Compute Tomography Imaging (dpeaa)DE-He213 Invasive Lobular Carcinoma (dpeaa)DE-He213 Tumor Shape (dpeaa)DE-He213 Maximum Tumor Size (dpeaa)DE-He213 Akashi-Tanaka, Sadako aut Miyakawa, Kunihisa aut Hojo, Takashi aut Shimizu, Chikako aut Seki, Kunihiko aut Ando, Masashi aut Kohno, Tsutomu aut Taira, Naruto aut Doihara, Hiroyoshi aut Katsumata, Noriyuki aut Fujiwara, Yasuhiro aut Kinoshita, Takayuki aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 33(2008), 1 vom: 25. Okt., Seite 44-51 (DE-627)SPR003391159 nnns volume:33 year:2008 number:1 day:25 month:10 pages:44-51 https://dx.doi.org/10.1007/s00268-008-9800-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 33 2008 1 25 10 44-51 |
| allfieldsSound |
10.1007/s00268-008-9800-9 doi (DE-627)SPR003420027 (SPR)s00268-008-9800-9-e DE-627 ger DE-627 rakwb eng Shien, Tadahiko verfasserin aut Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2008 Background Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. Methods From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. Results The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. Conclusions In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane. Trastuzumab (dpeaa)DE-He213 Compute Tomography Imaging (dpeaa)DE-He213 Invasive Lobular Carcinoma (dpeaa)DE-He213 Tumor Shape (dpeaa)DE-He213 Maximum Tumor Size (dpeaa)DE-He213 Akashi-Tanaka, Sadako aut Miyakawa, Kunihisa aut Hojo, Takashi aut Shimizu, Chikako aut Seki, Kunihiko aut Ando, Masashi aut Kohno, Tsutomu aut Taira, Naruto aut Doihara, Hiroyoshi aut Katsumata, Noriyuki aut Fujiwara, Yasuhiro aut Kinoshita, Takayuki aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 33(2008), 1 vom: 25. Okt., Seite 44-51 (DE-627)SPR003391159 nnns volume:33 year:2008 number:1 day:25 month:10 pages:44-51 https://dx.doi.org/10.1007/s00268-008-9800-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 33 2008 1 25 10 44-51 |
| language |
English |
| source |
Enthalten in World Journal of Surgery 33(2008), 1 vom: 25. Okt., Seite 44-51 volume:33 year:2008 number:1 day:25 month:10 pages:44-51 |
| sourceStr |
Enthalten in World Journal of Surgery 33(2008), 1 vom: 25. Okt., Seite 44-51 volume:33 year:2008 number:1 day:25 month:10 pages:44-51 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Trastuzumab Compute Tomography Imaging Invasive Lobular Carcinoma Tumor Shape Maximum Tumor Size |
| isfreeaccess_bool |
false |
| container_title |
World Journal of Surgery |
| authorswithroles_txt_mv |
Shien, Tadahiko @@aut@@ Akashi-Tanaka, Sadako @@aut@@ Miyakawa, Kunihisa @@aut@@ Hojo, Takashi @@aut@@ Shimizu, Chikako @@aut@@ Seki, Kunihiko @@aut@@ Ando, Masashi @@aut@@ Kohno, Tsutomu @@aut@@ Taira, Naruto @@aut@@ Doihara, Hiroyoshi @@aut@@ Katsumata, Noriyuki @@aut@@ Fujiwara, Yasuhiro @@aut@@ Kinoshita, Takayuki @@aut@@ |
| publishDateDaySort_date |
2008-10-25T00:00:00Z |
| hierarchy_top_id |
SPR003391159 |
| id |
SPR003420027 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR003420027</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519101528.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201001s2008 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00268-008-9800-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR003420027</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00268-008-9800-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shien, Tadahiko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2008</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Société Internationale de Chirurgie 2008</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. Methods From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. Results The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. Conclusions In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Trastuzumab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Compute Tomography Imaging</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Invasive Lobular Carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tumor Shape</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Maximum Tumor Size</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akashi-Tanaka, Sadako</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miyakawa, Kunihisa</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hojo, Takashi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shimizu, Chikako</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seki, Kunihiko</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ando, Masashi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kohno, Tsutomu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taira, Naruto</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Doihara, Hiroyoshi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Katsumata, Noriyuki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fujiwara, Yasuhiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kinoshita, Takayuki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">World Journal of Surgery</subfield><subfield code="d">Springer-Verlag, 1996</subfield><subfield code="g">33(2008), 1 vom: 25. Okt., Seite 44-51</subfield><subfield code="w">(DE-627)SPR003391159</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:33</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:1</subfield><subfield code="g">day:25</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:44-51</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00268-008-9800-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">33</subfield><subfield code="j">2008</subfield><subfield code="e">1</subfield><subfield code="b">25</subfield><subfield code="c">10</subfield><subfield code="h">44-51</subfield></datafield></record></collection>
|
| author |
Shien, Tadahiko |
| spellingShingle |
Shien, Tadahiko misc Trastuzumab misc Compute Tomography Imaging misc Invasive Lobular Carcinoma misc Tumor Shape misc Maximum Tumor Size Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer |
| authorStr |
Shien, Tadahiko |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR003391159 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer Trastuzumab (dpeaa)DE-He213 Compute Tomography Imaging (dpeaa)DE-He213 Invasive Lobular Carcinoma (dpeaa)DE-He213 Tumor Shape (dpeaa)DE-He213 Maximum Tumor Size (dpeaa)DE-He213 |
| topic |
misc Trastuzumab misc Compute Tomography Imaging misc Invasive Lobular Carcinoma misc Tumor Shape misc Maximum Tumor Size |
| topic_unstemmed |
misc Trastuzumab misc Compute Tomography Imaging misc Invasive Lobular Carcinoma misc Tumor Shape misc Maximum Tumor Size |
| topic_browse |
misc Trastuzumab misc Compute Tomography Imaging misc Invasive Lobular Carcinoma misc Tumor Shape misc Maximum Tumor Size |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
World Journal of Surgery |
| hierarchy_parent_id |
SPR003391159 |
| hierarchy_top_title |
World Journal of Surgery |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR003391159 |
| title |
Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer |
| ctrlnum |
(DE-627)SPR003420027 (SPR)s00268-008-9800-9-e |
| title_full |
Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer |
| author_sort |
Shien, Tadahiko |
| journal |
World Journal of Surgery |
| journalStr |
World Journal of Surgery |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2008 |
| contenttype_str_mv |
txt |
| container_start_page |
44 |
| author_browse |
Shien, Tadahiko Akashi-Tanaka, Sadako Miyakawa, Kunihisa Hojo, Takashi Shimizu, Chikako Seki, Kunihiko Ando, Masashi Kohno, Tsutomu Taira, Naruto Doihara, Hiroyoshi Katsumata, Noriyuki Fujiwara, Yasuhiro Kinoshita, Takayuki |
| container_volume |
33 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Shien, Tadahiko |
| doi_str_mv |
10.1007/s00268-008-9800-9 |
| title_sort |
clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer |
| title_auth |
Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer |
| abstract |
Background Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. Methods From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. Results The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. Conclusions In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane. © Société Internationale de Chirurgie 2008 |
| abstractGer |
Background Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. Methods From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. Results The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. Conclusions In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane. © Société Internationale de Chirurgie 2008 |
| abstract_unstemmed |
Background Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. Methods From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. Results The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. Conclusions In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane. © Société Internationale de Chirurgie 2008 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer |
| url |
https://dx.doi.org/10.1007/s00268-008-9800-9 |
| remote_bool |
true |
| author2 |
Akashi-Tanaka, Sadako Miyakawa, Kunihisa Hojo, Takashi Shimizu, Chikako Seki, Kunihiko Ando, Masashi Kohno, Tsutomu Taira, Naruto Doihara, Hiroyoshi Katsumata, Noriyuki Fujiwara, Yasuhiro Kinoshita, Takayuki |
| author2Str |
Akashi-Tanaka, Sadako Miyakawa, Kunihisa Hojo, Takashi Shimizu, Chikako Seki, Kunihiko Ando, Masashi Kohno, Tsutomu Taira, Naruto Doihara, Hiroyoshi Katsumata, Noriyuki Fujiwara, Yasuhiro Kinoshita, Takayuki |
| ppnlink |
SPR003391159 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s00268-008-9800-9 |
| up_date |
2024-07-03T19:24:26.951Z |
| _version_ |
1803587070934908928 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR003420027</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519101528.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201001s2008 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00268-008-9800-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR003420027</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00268-008-9800-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shien, Tadahiko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2008</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Société Internationale de Chirurgie 2008</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. Clinical and pathological responses are important prognostic parameters for NC, which aims to achieve a pathological complete response or tumor reduction to reduce the volume of subsequent breast resection. Clinicopathological markers that predict patient response to NC are needed to individualize treatment. Methods From 1998 to 2006, 368 patients with primary breast cancer underwent curative surgical treatment after NC (anthracycline and/or taxane without trastuzumab). We retrospectively evaluated the clinicopathological features and classification of the tumors using computed tomography (CT) before NC and analyzed the correlation with the pathological complete response (pCR) and reduction of tumor size after treatment. Results The overall response and pCR rates in these patients were 86% and 17%, respectively. In multivariate analysis, classification as a scirrhous-type tumor was an independent predictor of reduced likelihood of pCR (p = 0.0115; odds ratio 0.21). For tumor reduction, histological grade 3 (p = 0.0002; odds ratio 3.3) and localized tumors identified by using CT imaging (p = 0.0126; odds ratio 2.4) were independent predictors in multivariate analysis. Conclusions In this study, NC often did not result in pCR for breast cancers classified as scirrhous. Furthermore, tumor type classification using CT imaging and histological grading was effective to predict tumor reduction in response to NC that included an anthracycline and/or a taxane.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Trastuzumab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Compute Tomography Imaging</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Invasive Lobular Carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tumor Shape</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Maximum Tumor Size</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akashi-Tanaka, Sadako</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miyakawa, Kunihisa</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hojo, Takashi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shimizu, Chikako</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seki, Kunihiko</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ando, Masashi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kohno, Tsutomu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taira, Naruto</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Doihara, Hiroyoshi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Katsumata, Noriyuki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fujiwara, Yasuhiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kinoshita, Takayuki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">World Journal of Surgery</subfield><subfield code="d">Springer-Verlag, 1996</subfield><subfield code="g">33(2008), 1 vom: 25. Okt., Seite 44-51</subfield><subfield code="w">(DE-627)SPR003391159</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:33</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:1</subfield><subfield code="g">day:25</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:44-51</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00268-008-9800-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">33</subfield><subfield code="j">2008</subfield><subfield code="e">1</subfield><subfield code="b">25</subfield><subfield code="c">10</subfield><subfield code="h">44-51</subfield></datafield></record></collection>
|
| score |
7.3995314 |